 "Cipla to invest Rs 1000 crore in UK")
Cipla Ltd, in collaboration with the UK government, has expressed its intention to make investments of up to GBP 100 million (about Rs 1028 crore) in its UK subsidiary over the next few years. The investments are expected to facilitate the launch of a range of products in the area of respiratory, oncology and antiretroviral medicines to further Cipla’s higher purpose of ‘universal affordable access’.
Cipla also plans to invest in R&D activities, clinical trials and expand further internationally. “The investment underscores the growing importance of UK in Cipla’s long term strategy,” said the company in a BSE filing.
Cipla has been fortifying its global base in last couple of years. Last month itself, in a two separate deals, Cipla acquired majority stakes in a Yemeni and a Sri Lankan company. In 2013, it had acquired Quality Chemical Industries (Uganda), Celeris (Croatia) and Medpro (South Africa).
Cipla also plans to invest in R&D activities, clinical trials and expand further internationally. “The investment underscores the growing importance of UK in Cipla’s long term strategy,” said the company in a BSE filing.
Cipla has been fortifying its global base in last couple of years. Last month itself, in a two separate deals, Cipla acquired majority stakes in a Yemeni and a Sri Lankan company. In 2013, it had acquired Quality Chemical Industries (Uganda), Celeris (Croatia) and Medpro (South Africa).